Prostate cancer is the most diagnosed cancer among men in the United States and the second most prevalent cancer in men worldwide (1,2). MRI can better triage patients to undergo biopsy, while providing information about tumors and treatment progress (4). However, there are challenges with MRI image quality, the interpretation of the images, and the potential for false positives and negatives. With the annual number of prostate exams rapidly increasing (5), there is a need for accurate and reliable prostate MRI interpretation. One proposed approach is to use an AI-based lesion detection software in addition to radiologists' interpretations. The Siemens Healthineers ("Siemens") business lines Digital \& Automation ("D\&A") and Magnetic Resonance ("MR") have developed the AI Rad Companion Prostate MRI (AIRC), which aids in the detection of potential prostate cancer. The goal of this study is to investigate the effects of the use of AIRC in improving the standard of care in prostate cancer detection and treatment. Participation in the study will be about an hour to review the consent form. All other study procedures (MRI, biopsy) will be standard of care.
